The case of a 45-year-old woman with gyrate atrophy and hyperornithinaemia is documented here. She has been followed up for 12 years and fully investigated.
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Additional features in this case, to our knowledge not pre viously described in gyrate atrophy, are massive cystinu ria, massive Iysinuria, axial hypermetropia and diabetes.
CASE REPORT
A then 36-year-old Asian woman was first seen in 1982 with a history of night blindness and progressive visual loss of well over 10 years. She had no history of parental consanguinity and one male and three female siblings had no visual problems. The patient has a 24-year-old son with no visual symptoms or ocular abnormality. She was diag- 
UK.
Correspondence (Fig. 1) shows the characteristic garland-shaped chorioretinal foci of gyrate atrophy. There are large numbers of scattered areas of retinal pigment epithelium transmission defects.
Chorioretinal atrophy is so prominent that only large chor oidal blood vessels are seen against the whitish back ground of sclera ( Fig. 2 ).
Serum ornithine was 790 flmol/l on initial presentation.
Quantitative analysis of 24 hour urine amino acids (Table   1) shows a striking increase in ornithine, cystine and lysine. Systemic pyridoxine (vitamin B6) therapy was instituted between August 1983 and April 1984 with a starting dose of lOO mg daily increasing to 600 mg daily.
There was an initial but short-lived fall in serum ornithine by 40%, but in spite of high doses this was not maintained.
The patient was considered a non-responder to pyridoxine.
The patient underwent bilateral cataract extraction '0 with intraocular lens implants in 1985 (left eye) and 1990
(right eye). Posterior chamber lenses of +25 dioptres were implanted to achieve emmetropia based on biometry. With the patient's prior consent, at the time of cataract extrac tion aqueous specimens were obtained through the clear cornea using a 30G hypodermic needle on a tuberculin syringe. Analysis of amino acids in serum, urine and aque ous (Table II) showed raised ornithine in the blood and the aqueous. Whilst the urine showed generalised amino- 17 The exact mechanism by which the OAT defi ciency and hyperornithinaemia lead to chorioretinal degeneration is not known. Two clinical SUbtypes of gyrate atrophy have been described based upon the in vivo or in vitro response to vitamin B6. Pyridoxal phosphate (PLP), a co-enzyme of OATase, administered as pharmacological doses of vita min B6 lowers the ornithine level in a small number of patients. I X -cO B6 responsiveness is manifested by an approximate 50% reduction in serum ornithine levels and normalisation of serum lysine. Patients responsive to vita min B6 have less severe disease and slow progression, while non-responders to vitamin B6 have severe disease and rapid progression to blindness. Less than 10% of gyrate atrophy patients reported in the literature are B6 responders.I,.I X . 21 OAT is a nuclear-encoded, vitamin-B6-requiring, mito chondrial enzyme that catalyses the interconversion of ornithine, glutamate and proline.22 It is the main catabolic enzyme of ornithine and a defect in OAT would result in hyperornithinaemia as seen in gyrate atrophy. Several recent studies have reported on the results of cloning and analysis of the human OAT structural gene (molecular genetic approach).21-2 6 Obligate heterozygotes have one normal active allele of the OAT gene which is responsible In clinical practice it is usually the onset of myopia that leads to the first consultation and a definitive diagnosis made in childhood or the early teens. The patient pre sented above was born in the Indian subcontinent. She shows the ophthalmic, biochemical and genetic character istics of typical gyrate atrophy associated with hyper ornithinaemia. As opposed to cases reported in the literature of mild to high myopia, she is hypermetropic. This suggests that myopia is not a constant feature in gyrate atrophy. This case also demonstrates strikingly high levels of urinary cystine and lysine. Some increase in the levels of these two amino acids is expected with high levels of ornithine, as these di-basic amino acids share the same renal transport mechanism. We have been unable to find any reference to an increase of this magnitude and she is considered to be at risk from cystine stone formation in the urinary tract. A recent intravenous pyelogram has been reported as normal. This case of gyrate atrophy supports additional information of renal tubular dysfunction. Association of diabetes with gyrate atrophy has not been M. Y. KHAN ET AL.
identified before. It remains to be established whether these metabolic disorders are related in any specific way. A diabetic for 20 years, this patient shows no evidence of retinopathy whatsoever. In view of the extensive chor ioretinal atrophy one would expect this protection, as the metabolic needs of the retina are reduced. It is assumed that the effect has a similar mechanism to that of panret inal photocoagulation. 2 5 
